6-ECDCA

Confirm delete?

6-ECDCA

Zoom

Cat No: 11031

Farnesoid X receptor (FXR) is a nuclear receptor that is activated by bile acid, with chenodeoxycholic acid (CDCA) being a representative natural ligand.{20706} 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of FXR (EC50 =...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

(3?,5?,6?,7?)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid

Correlated keywords:

OCA 6ECDCA INT747

Product Overview:
Farnesoid X receptor (FXR) is a nuclear receptor that is activated by bile acid, with chenodeoxycholic acid (CDCA) being a representative natural ligand.{20706} 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of FXR (EC50 = 99 nM).{20705} Through FXR, it alters gene expression that results in protection against cholestasis as well as liver fibrosis.{20705,20702,20703} 6-ECDCA also, through FXR, promotes the differentiation of adipocytes and enhances insulin signaling in mature adipocytes.{20707} In ApoE-/- mice, 6-ECDCA ameliorates vascular calcification secondary to chronic kidney disease without affecting the development of atherosclerosis.{20704}

Size	5 mg
Shipping	dry ice
CAS Number	459789-99-2
Molecular Formula	C₂₆H₄₄O₄
SMILES	O[C@@H]1CC[C@@]2(C)[C@@]([C@@H](CC)[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@H](CCC(O)=O)C)([H])C1
Molecular Weight	420,6
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2937.29
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.